



University of Warwick institutional repository: <http://go.warwick.ac.uk/wrap>

This paper is made available online in accordance with publisher policies. Please scroll down to view the document itself. Please refer to the repository record for this item and our policy information available from the repository home page for further information.

To see the final version of this paper please visit the publisher's website. Access to the published version may require a subscription.

Author(s): Muse Oke, Lester G. Carter, Kenneth A. Johnson, Huanting Liu, Stephen A. McMahon, Xuan Yan, Melina Kerou, Nadine D. Weikart, Nadia Kadi, Md. Arif Sheikh, Stefan Schmelz, Mark Dorward, Michal Zawadzki, Christopher Cozens, Helen Falconer, Helen Powers, Ian M. Overton, C. A. Johannes van Niekerk, Xu Peng, Prakash Patel, Roger A. Garrett, David Prangishvili, Catherine H. Botting, Peter J. Coote, David T. F. Dryden, Geoffrey J. Barton, Ulrich Schwarz-Linek, Gregory L. Challis, Garry L. Taylor, Malcolm F. White and James H. Naismith  
Article Title: The Scottish Structural Proteomics Facility: targets, methods and outputs

Year of publication: 2010

Link to published article:

<http://dx.doi.org/10.1007/s10969-010-9090-y>

Publisher statement: The original publication is available at [www.springerlink.com](http://www.springerlink.com)

## The Scottish Structural Proteomics Facility: targets, methods and outputs

Muse Oke · Lester G. Carter · Kenneth A. Johnson · Huanting Liu · Stephen A. McMahon · Xuan Yan · Melina Kerou · Nadine D. Weikart · Nadia Kadi · Md. Arif Sheikh · Stefan Schmelz · Mark Dorward · Michal Zawadzki · Christopher Cozens · Helen Falconer · Helen Powers · Ian M. Overton · C. A. Johannes van Niekerk · Xu Peng · Prakash Patel · Roger A. Garrett · David Prangishvili · Catherine H. Botting · Peter J. Coote · David T. F. Dryden · Geoffrey J. Barton · Ulrich Schwarz-Linek · Gregory L. Challis · Garry L. Taylor · Malcolm F. White · James H. Naismith

Received: 9 March 2010 / Accepted: 6 April 2010 / Published online: 24 April 2010  
© The Author(s) 2010. This article is published with open access at Springerlink.com

**Abstract** The Scottish Structural Proteomics Facility was funded to develop a laboratory scale approach to high throughput structure determination. The effort was successful in that over 40 structures were determined. These structures and the methods harnessed to obtain them are reported here. This report reflects on the value of automation but also on the continued requirement for a high

degree of scientific and technical expertise. The efficiency of the process poses challenges to the current paradigm of structural analysis and publication. In the 5 year period we published ten peer-reviewed papers reporting structural data arising from the pipeline. Nevertheless, the number of structures solved exceeded our ability to analyse and publish each new finding. By reporting the experimental details and depositing the structures we hope to maximize the impact of the project by allowing others to follow up the relevant biology.

Muse Oke, Lester G. Carter, Kenneth A. Johnson, Huanting Liu, Stephen A. McMahon—Joint first authors.

**Electronic supplementary material** The online version of this article (doi:10.1007/s10969-010-9090-y) contains supplementary material, which is available to authorized users.

**Keywords** High-throughput · Protein crystallography · Structural proteomics · SSPF

M. Oke · L. G. Carter · K. A. Johnson · H. Liu · S. A. McMahon · X. Yan · M. Kerou · N. D. Weikart · Md. A. Sheikh · S. Schmelz · M. Dorward · M. Zawadzki · C. Cozens · H. Falconer · H. Powers · C. H. Botting · P. J. Coote · U. Schwarz-Linek · G. L. Taylor · M. F. White · J. H. Naismith (✉)  
Biomedical Sciences Research Complex, University of St Andrews, St Andrews KY16 9ST, UK  
e-mail: naismith@st-and.ac.uk

N. Kadi · P. Patel · G. L. Challis  
Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK

*Present Address:*  
N. Kadi  
Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK

*Present Address:*  
L. G. Carter  
Stanford Synchrotron Radiation Light Source, 2575 Sand Hill Road, MS 69, Menlo Park, CA 94025, USA

*Present Address:*  
M. Dorward  
Division of Signal Transduction Therapy, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK

*Present Address:*  
K. A. Johnson  
The Norwegian Structural Biology Centre, University of Tromsø, 9037 Tromsø, Norway

*Present Address:*  
M. Zawadzki  
Syngenta Ltd, Jealott's Hill International Research Centre, Bracknell, Berkshire RG42 6EY, UK

*Present Address:*  
N. D. Weikart  
Faculty of Chemistry, Technische Universität Dortmund, Otto-Hahn-Str. 6, 44227 Dortmund, Germany

*Present Address:*  
C. Cozens  
Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK

## Abbreviations

BLAST	Basic local alignment search tool
PDB	Protein data bank
PDRA	Post-doctoral research associates
PONDR	Predictor of natural disordered regions
RONN	Regional order neural network
SGC	Structural genomics consortium
SPINE	Structural proteomics in Europe
SPoRT	Structural proteomics of rational targets
SSPF	Scottish Structural Proteomics Facility

## Introduction

Structural biology is firmly embedded as a crucial tool for the molecular biologist, whether the interest is academic or commercial. The genome sequencing revolution of the 1990s transformed the biological landscape and to remain relevant to the scale of this new information, structural biology had to accelerate its pace of discovery. The Scottish Structural Proteomics Facility (SSPF) comprised of four partner institutions: the Universities of St Andrews, Dundee, Glasgow and Warwick. The Structural Proteomics of Rational Targets (SPoRT) laboratory situated at the University of St Andrews was established with the focus of developing small scale high throughput structural biology and to facilitate collaboration with other universities. Much larger international efforts have focussed on

productivity and throughput as exemplified by the NIH Protein Structure Initiative in the USA, Protein 3000 in Japan, Structural Proteomics in Europe (SPINE) [1] and the international Wellcome Trust Structural Genomics Consortium (SGC) [2]. Our remit was to generate structures, publications and to facilitate access for “non-structural” labs to structural biology. The “high throughput” lab commenced work in 2004 and focussed on development of efficient strategies for target selection, cloning, protein production, crystallization and crystal structure determination. Due to demands for higher throughput, automated equipment was employed at several key stages in the pipeline.

We chose targets against the following criteria: obtaining a structure was likely to be tractable (in essence this meant expression in *Escherichia coli*); the protein was likely to have a novel structure; the structure had the potential to either underpin antibiotic development or illuminate some defined aspect of biology or biochemistry. As we discuss, one of the significant challenges was to balance choice of “publishable” target work against the work of running the pipeline and the tractability of target (including any subsequent biochemical investigation). Target selection thus differed from many other efforts which focus on folds predicted to be “novel” (exemplified by the NIH efforts) or on comprehensive coverage of a functional class (such as the focus on short chain dehydrogenases and kinases of the SGC).

During the build up of the SPoRT pipeline, we operated structure determination in essentially a traditional manner, in that projects were processed without automation in a sequential manner. This was because the funding imposed a number of output milestones which had to be met, thus there are “high throughput” structures and “low throughput” structures. The St Andrews laboratory was funded by a combination of sources and its staff complement consisted primarily of five post-doctoral research associates (PDRA) and two technicians. In 4 years, we have cloned more than 350 genes resulting in the production of 165 proteins from which 42 have yielded crystal structures. This represents about 25% of purified proteins that made it to crystal structure. Another measure of efficiency is that in its lifetime the pipeline delivered over two structures per PDRA per year. Given that the pipeline only became operative from the second year, the efficiency metrics by the end of the project were significantly higher than the beginning. However, the success of the pipeline outstripped our ability to analyse and follow up the structures. In this report, we provide a detailed account of the pipeline, the experimental structural biology and highlight some of the issues we faced. This strategy allows others to reproduce the experiments and to pursue the biological implications of our work.

### Present Address:

H. Falconer  
Institute of Structural and Molecular Biology, Edinburgh  
University, Kings Buildings, Edinburgh EH9 3JR, UK

I. M. Overton · C. A. J. van Niekerk · G. J. Barton  
Division of Biological Chemistry and Drug Discovery,  
College of Life Sciences, University of Dundee,  
Dundee DD1 5EH, Scotland, UK

### Present Address:

I. M. Overton  
MRC Human Genetics Unit, Crewe Road South,  
Edinburgh EH4 2XU, UK

X. Peng · R. A. Garrett  
Department of Biology, Archaea Centre,  
University of Copenhagen, Ole Maaløes Vej 5, 2200,  
Copenhagen N, Denmark

D. Prangishvili  
Institut Pasteur, 25 rue Dr. Roux, 75724 Paris cedex 15, France

D. T. F. Dryden  
EaStChem School of Chemistry, University of Edinburgh,  
The King's Buildings, Edinburgh EH9 3JJ, UK

## Materials and methods

### Bioinformatics analyses for target selection

Proteins were submitted to the pipeline as cohorts of targets; collection of genes with a common theme or source. Proteins were then analysed using a standard suite of analyses: SignalP 3.0 to detect signal peptides which indicate the protein would otherwise normally be exported from the cytoplasm [3]; TMHMM2 to detect transmembrane regions which may reduce protein solubility [4]; and RONN and PONDR to analyze the sequence for predicted disordered regions which are believed to interfere with crystallization [5, 6]. As a result of these analyses, truncations were made in a few cases where the prediction suggested significant disorder at the C- or N- termini, signal peptides or transmembrane regions. BLAST searches of the PDB were carried out to establish the originality and potential impact of the structure. Targets were also analysed using the pI versus GRAVY crystallization predictor plot as described in [7]. This work was initially carried out manually or by basic PERL scripts. However, a core part of the SSPF was to develop improved techniques for target selection, so in order to streamline and improve the ease and reliability of target selection we developed an automated system for carrying out sequence analysis called TarO [8]. TarO runs a suite of analyses on a target sequence including orthology detection and returns a summarised view of the findings as well as an annotated multiple sequence alignment that assists in the identification of domain boundaries and disordered regions. The system is web-accessible and has been used extensively within the SSPF as well as by external users world-wide. In addition to TarO, three techniques for crystallisation propensity prediction were also developed. The OB-Score [9] combines hydrophobicity and predicted pI within a statistical framework, the ParCrys algorithm combines more features of the sequence [10] while XANNpred (manuscript submitted) is a machine-learning technique that includes a broad range of properties including predicted

secondary structure. TarO presents results sorted by ParCrys and the OB-Score to highlight proteins which may be more amenable to processing in the SSPF high-throughput pipeline. While TarO and the crystallisation predictors were not applied in all structures output by SSPF, they were input to decision making processes in the later years of the project.

### Genome-wide scale target selection tools

We also developed bioinformatics protocols for large-scale target selection. A round of target selection was conducted to select tractable prokaryotic proteins expected to be relevant to human biology. The 657,391 proteins in the CMR ('Omniome') database [11] was the starting point for this work. The progress of these proteins through the target selection filters is summarised in Table 1. Proteins predicted to be amenable to producing diffraction-quality crystals (OB-Score  $\geq 5$ ) were searched against Ensembl human [12] with PSIBLAST [13], which identified 55,405 matches with expected structural similarity according to published thresholds [14]. In order to explore novel structure space, proteins with a match to the PDB [15] were excluded, leaving 4,461 proteins. Uniprot [16] identifiers were inferred to provide a mechanism for obtaining pre-calculated annotations, particularly Pfam [17] and Gene Ontology (GO) [18] data. Proteins were excluded by the criteria of one or more predicted TMHMM2 transmembrane regions, sequence length outwith 60–600 amino acids, and more than 20% predicted SEG low-complexity [19]. A total of 344 Pfam families were inferred for 3,008 proteins that passed the above filters. The total set of sequences from the 344 Pfam families were searched against the PDB (BLASTP, 1E-6, 90% identify, 90% query coverage) to exclude proteins where a homology modelling template was available. The final filtered set contained 1,329 proteins from 143 Pfam families. These proteins were then ranked according to OB-Score, and a custom scoring system 'SOFA' (see below).

**Table 1** CMR target selection summary

Filter summary	No. of proteins post filtering
All CMR proteins	657,391
OB-Score $\geq 5$	197,000
PSIBLAST match <sup>a</sup> to Ensembl human protein	55,405
No PSIBLAST match <sup>a</sup> to PDB	4,461
Assign UniProt ID <sup>b</sup>	4,306
No TMHMM transmembrane regions & $\leq 20\%$ SEG low-complexity, sequence length 60–600 amino acids	3,508
Infer Pfam family	3,008 (344 families)
No structure in Pfam family	1,329 (143 families)

<sup>a</sup> Matches defined by Rost curve [14]


<sup>b</sup> Uniprot identifiers inferred by perfect sequence match or BLASTP (1E-6, 90% query coverage, 90% identity)

A Gene Ontology-based scoring system (Specificity Of Functional Annotation, ‘SOFA’) was implemented to estimate the extent of available functional annotation for candidate targets, because functional annotation is often important for interpretation of new protein structures. The GO term with the least number of children was the starting point for calculating a protein’s SOFA score. From this term, the ratio of the parent to child terms was calculated; higher scores indicated more parents and therefore estimated more knowledge was available about the protein’s function. Where proteins had leaf-node GO term(s) the SOFA score was always higher than for proteins with no leaf-node GO term. Also, a greater number of leaf node terms corresponded to higher scores.

Further large-scale target selection was conducted with the aim of identifying tractable proteins relevant to *Staphylococcus aureus* therapeutics development. A set of 253 identifiers were taken from the literature [20, 21], indicating genes essential for infectivity in mouse models and/or essential for viability for growth in rich media. These were mapped to 1637 *S. aureus* proteins in CMR, corresponding to 1 MSSA (MSSA476) and 5 MRSA (MRSA252, Mu50, COL, MW2, and N315) strains. These proteins were subject to a series of filters similar to those described above. The filtering criteria were OB-Score  $\geq 3$ ,  $<2$  TMHMM2 transmembrane regions,  $\leq 20\%$  SEG low-complexity, sequence length 60–600 amino acids. PSI-BLAST matches to PDB and Ensembl human proteins were excluded according to published thresholds. Matches to human proteins were excluded because these were considered to be less attractive therapeutic targets. Pfam matches were inferred, leaving 51 proteins from 36 Pfam families and 50 proteins without a Pfam match. SOFA scoring was applied to these 101 proteins and further analyses of these proteins including TarO and literature searching proposed a final set of 20 targets from 11 functional categories. This final set of 20 *S. aureus* proteins were submitted to the pipeline for production.

## Cloning

With the exception of purified proteins provided by collaborators, open reading frames (ORFs) of all targets were cloned using a modified version of the Gateway cloning system. Each target was cloned with an N-terminal TEV protease cleavable His<sub>6</sub> tag, with the BP recombination site relocated out of the cloning sequence. Target genes were amplified using one common and two gene-specific primers. The common primer, encoding the attB1 recombination site, RBS, ATG start codon, six histidine residues and TEV protease site (Fig. 1) was generated by PCR. The primers used for the above process were 5'-GGGGACAA GTTTGTACAAAAAAGCAGGCTTCGAAGGAGATATAC



**Fig. 1** Bar presentation of primers used for gene amplifications at SSPF. The 5' end common primer (co) is a double-stranded primer generated by PCR and used for cloning genes with the N-terminal TEV protease cleavable 6× His tag. The 5' end custom (gene-specific) primer (cu) contains overlap sequence of 30 bp with the common primer and the gene specific sequence of 23 bp. The 3' end custom (gene-specific) primer (cu) contains the gene-specific sequence of 23 bp and attB2 recombination site of 30 bp. AttB: BP recombination sites, RBS: ribosome binding site, ATG: start codon, 6× His: six histidine tag, TEV site: TEV site: sequence coding TEV protease cleavage site and the spacer. Numbers indicate the length of the primers (bp)

ATATG-3' (designated ATTF; attB1 site is in italics) and 5'-GCCCTGAAAATACAGGTTTC-3' (designated ATTR) with template of NdeI/NcoI-DNA fragments released from pEHISTEV plasmid DNA [22]. PCR products thus generated were purified by ethanol precipitation and resuspended to a final concentration of 4  $\mu$ M. Target genes were amplified in PCR reactions consisting of 5  $\mu$ l of each pair of gene-specific primers (10  $\mu$ M), 2.5  $\mu$ l of the common primers, 5  $\mu$ l of dNTP mixture (200  $\mu$ M each), 10  $\mu$ l of thermo polymerase buffer (5×) containing 2 mM MgSO<sub>4</sub> and 4% DMSO, 2 units of *Pfu* DNA polymerase and 10 ng of DNA template in a total volume of 50  $\mu$ l. Two-stage PCR amplifications were carried out in a 96-well formatted PCR plate. After denaturing the template at 95°C for 5 min, amplifications were carried out at 95°C for 1 min, Tm-5 for 1 min and 72°C for 4 min for 5 cycles and then followed by another 25 cycles using the same procedure except that an annealing temperature of 62°C was employed instead of Tm-5 to increase the specificity of the amplification. PCR products were cleaned using the PCR cleaning kit (Promega) and diluted to a concentration of 50 ng/ $\mu$ l.

BP recombination was carried out as described in the Gateway cloning instruction manual using pDONR221 as donor vector. The recombination reaction consisted of 100 ng of attB-PCR products, 100 ng of pDONR221 vector and 1  $\mu$ l of BP clonase II enzyme mix in TE buffer to a total volume of 10  $\mu$ l. The mixture was incubated at 25°C for 1 h and then further incubated at 37°C for 15 min following the addition of 2  $\mu$ l proteinase K. *E. coli* DH5 $\alpha$  chemical competent cells were transformed with 2  $\mu$ l reaction mix and the transformed cells were spread onto L-agar plates containing 50  $\mu$ g/ml kanamycin. Plasmid DNA was prepared by picking two colonies and cultivating in separate 10 ml L-broth media containing 50  $\mu$ g/ml kanamycin, prior to insert verification by agarose gel electrophoresis.

LR recombination was carried out using pDEST14 as the destination vector with two verified pDONR221 clones. The recombination reaction contained 100 ng of entry clone pDONR221 DNA, 100 ng of pDEST14 vector, 1  $\mu$ l of LR clonase II enzyme mix in TE buffer to a total volume of 10  $\mu$ l. The reaction mixture was incubated for 1 h at 25°C and then incubated at 37°C for 15 min after adding 2  $\mu$ l of proteinase K. A total volume of 2  $\mu$ l of each BP reaction was transformed into 50  $\mu$ l of DH5 $\alpha$  chemical competent cells and selected for ampicillin resistance on an L-agar plate. Two clones were picked and the plasmid DNA isolated for each LR reaction. The insertion sequence of each clone was verified and the prepared DNA was stored at -80°C for expression trials.

### Small-scale expression

The *E. coli* competent cells BL21 (DE3), C43 (DE3), and BL21 (DE3)-CodonPlus (Stratagene) were transformed with the pDEST14 expression vectors. Small-scale expression trials were carried out in Lysogeny Broth (LB; 10 g Tryptone, 5 g Yeast Extract, 10 g NaCl), Tryptone phosphate broth (TPB; 20 g Tryptone, 2 g K<sub>2</sub>HPO<sub>4</sub>, 2 g KH<sub>2</sub>PO<sub>4</sub>, 5 g NaCl) and auto-induction media, prepared in-house using the recipe from [23] or purchased as 'Magic Media' (Invitrogen). For LB and TPB cultures, starter cultures were prepared by inoculating LB supplemented with ampicillin (final concentration 100  $\mu$ g/ml) with freshly-transformed colonies on LB/ampicillin plates, and incubating overnight at 37°C, 200 rpm. Alternatively, the transformation mix was used directly as inoculum for starter cultures. Growth media (5 ml) in 50 ml Falcon tubes was inoculated with overnight starter culture (1:100 dilution factor) prior to incubation at 37°C, 200 rpm. At mid-log growth phase (OD<sub>600</sub> ~ 0.6–0.8), protein expression was induced with 0.4 mM IPTG. For LB cultures, incubation continued for a further 3 h at 37°C for one set of cultures, whilst another set was incubated at 25°C overnight. TPB cultures were incubated overnight at 25°C and 15°C post-induction. For protein expression in auto-induction media, freshly transformed colonies were used to inoculate 3-ml auto-induction media supplemented with 100  $\mu$ g/ml ampicillin (two colonies per target protein). Cultures were then incubated at 37°C, 300 rpm until cultures turned slightly turbid at which point one set was further incubated at 37°C and the other set at 25°C, both for 42 h. Cultures were harvested by centrifugation and pellets were stored at -20°C. Cell lysis was achieved either chemically using Bugbuster HT solution (Novagen) or mechanically by sonication. Whole cell lysates were analysed for target protein expression by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE; [24] using pre-cast gels (Invitrogen). For target protein

localization, cell lysates were spun down and the supernatant was analysed for His<sub>6</sub>-tagged soluble protein expression using the BioSprint 15 workstation according to manufacturer's instructions (Qiagen). The resulting eluates were analysed by SDS-PAGE. Soluble protein expression was scored on the basis of whether protein bands commensurate with the estimated molecular weight were identified on SDS-PAGE gels. Band intensities were used to estimate the amount of soluble protein expressed. For uniformity, protein expression at <5 mg/l (low expression) was classified as 1S, 5–10 mg/l (medium expression) as 2S, and >10 mg/l (high expression) as 3S.

### Large-scale expression of target proteins

Protein identities were verified by mass spectrometry prior to scale-up. Overnight starter cultures were used to inoculate 1–6 l (depending on expression levels obtained from small-scale solubility screening experiments) LB, TPB or auto-induction media supplemented with ampicillin. Optimal growth conditions from small-scale expression trials were replicated for large scale expression. Prior to harvesting (centrifugation at 2,400 $\times$ g, for 30 min at 4°C), 1-ml aliquots were analyzed for protein expression and to estimate final yields. Cell pellets were stored at -80°C until required for purification.

Where appropriate, selenomethionine-labelled proteins were produced using the method of [25]. Essentially, freshly transformed BL21(DE3) or B834(DE3) cells served as inoculum for starter cultures. After overnight incubation, starter cultures were pelleted and washed 3 times with phosphate buffer (1 g NH<sub>4</sub>Cl, 3 g KH<sub>2</sub>PO<sub>4</sub>, 6 g Na<sub>2</sub>HPO<sub>4</sub> · 7H<sub>2</sub>O/l) prior to inoculation (1:20) of selenomethionine-incorporation media prepared as follows: 100 ml glucose solution (20% glucose, 0.3% MgSO<sub>4</sub>, 0.01% Fe<sub>2</sub>(SO<sub>4</sub>)<sub>3</sub>, 0.01% thiamine) was added to 900 ml phosphate buffer (same as above). The pH of the media was adjusted to 7.4 prior to addition of ampicillin and 50 mg/l L-(+) Selenomethionine. Cells were cultivated at 37°C until OD<sub>600</sub> was between 0.8 and 1.0, at which point IPTG was added to a final concentration of 0.2 mM. Cultures were incubated at 25°C overnight, harvested and stored as described above.

### Preparation of His<sub>6</sub>-tagged tobacco etch virus (TEV) protease

The *E. coli* recombinant strain BL21 (DE3)-RIL/pRK793 harbouring a mutant (S219V) of the catalytic domain of TEV protease was kindly donated by Partho Ghosh (Department of Chemistry and Biochemistry, University of California). This construct expresses as a maltose-binding protein (MBP) fusion protein that auto-cleaves in vivo, resulting in the TEV protease catalytic domain with

uncleavable N-terminal His<sub>6</sub> and C-terminal polyarginine tags [26]. Following protein expression at 25°C, the His<sub>6</sub>-TEV protease was purified by nickel-immobilized metal affinity chromatography (Ni<sup>2+</sup>-IMAC), followed by desalting chromatography. Aliquots (5 mg/ml) of TEV protease were prepared and stored at -80°C.

### Purification

Cell pellets were resuspended in buffer A (see below for all buffer constituents) supplemented with Dnase1 (Sigma) and EDTA-free protease inhibitor cocktail tablets (Roche) prior to cell lysis on ice using the One Shot cell disruptor (Constant Systems Ltd), continuously cooled with cold tap water. Cell lysate was clarified by centrifugation at 39,000×g for 1 h at 4°C and the supernatant was filtered using a 0.45 µm filter (Millipore) prior to purification. Fully-automated purification was carried out on the AKTExpress chromatography system using pre-packed columns (GE Healthcare). The purification procedure comprised of (1) Ni<sup>2+</sup>-immobilized metal affinity chromatography (Ni<sup>2+</sup>-IMAC) using buffers B and C for the wash and elution steps respectively (2) Desalting chromatography (DS) in buffer D for buffer exchange and removal of imidazole, (3) incubation with TEV protease for cleavage of the His<sub>6</sub> tag, (4) capture of the His<sub>6</sub>-tagged TEV protease on a second Ni<sup>2+</sup>-IMAC column and (5) Gel filtration chromatography (GF) in buffer E to separate out contaminants and aggregates from the target proteins. A schematic representation of the fully-automated version is shown in Fig. 2a. To facilitate on-line off-column cleavage of the His<sub>6</sub>-tag, a 50-ml superloop preloaded with His<sub>6</sub>-TEV protease was incorporated into the chromatography system. This arrangement facilitated the direct loading of the DS eluate into the TEV protease-loaded superloop. For manual purification, the Ni<sup>2+</sup>-IMAC and TEV cleavage steps were carried out on the bench, and the AKTExpress system was used for DS and GF. All proteins were purified at room temperature and analysed by SDS-PAGE. Aliquots of purified proteins were transferred into thin-walled PCR tubes and flash frozen in liquid nitrogen prior to storage at -80°C.

Buffer A: 20 mM sodium phosphate pH 7.4, 500 mM NaCl, 10% glycerol, 10–30 mM imidazole

Buffer B: 20 mM sodium phosphate pH 7.4, 500 mM NaCl, 10% glycerol, 30–50 mM imidazole

Buffer C: 20 mM sodium phosphate pH 7.4, 500 mM NaCl, 10% glycerol, 300 mM imidazole

Buffer D: 20 mM Tris pH 7.5, 500 mM NaCl, 10% glycerol

Buffer E: 10 mM Tris pH 7.5, 150 mM or 500 mM NaCl, 10% glycerol (optional)


### Crystallization

The pre-crystallization test (PCT) (Hampton Research) was used to determine the optimal protein concentration (OPC) for crystallization trials. All screening experiments were set up as sitting drops in 96-well crystallization plates at 2 or 3 protein concentrations using either the Cartesian Honeybee X8 + 1 in the Hamilton-Rhombix-Thermo integrated crystallization and imager system or an offline Cartesian Honeybee 963. Drop sizes consisting of 0.15 µl protein + 0.15 µl precipitant (protein concentrations: 1× OPC and 2× OPC) and 0.3 µl protein + 0.15 µl precipitant (protein concentration: 1× OPC) were employed. Initially 4 commercial crystallization screens chosen from JCSG+, Classics, Pegs, pHClear, Anions, Cations (Qiagen) and Wizard I & II (Emerald Biosystems) were used to screen all proteins. Eventually, this practice was phased out in favour of 3 stochastic screens [27] prepared in-house alongside the commercial JCSG+ screen. All screening experiments were incubated at 20°C and imaged at regular intervals with a Rhombix-Thermo imager.

The traditional grid screen approach around the initial hit condition(s) was used primarily for crystal optimization purposes. If this failed, a stochastic approach to optimization was often able to generate suitable single crystals. In both cases, 24 and 96 well grid/stochastic screens based on the original mother liquor were designed and built using a Hamilton Microlab Star and crystallization screens were then set either as before on one of the robots using nanoliter volumes or manually using larger µl drop sizes.

### Data collection and structure solution

Crystals deemed to be large enough for diffraction screening were harvested and frozen in liquid nitrogen. Crystals were characterized in house using a Rigaku Micromax<sup>TM</sup>-007HF Cu anode with VariMax optics alongside a Rigaku Saturn 944+ CCD detector and at various synchrotron beamlines including BM14, ID14-1, -2, -4, ID29 and ID 23-1 and -2 at the ESRF and IO2 and IO3 at the Diamond light source Oxfordshire. HKL2000 [28], MOSFLM [29], SCALA [30] and XDS [31] were all used at various times to index and scale data. Structures were phased by whatever method provided the fastest route to structure and included molecular replacement, sulfur-single wavelength anomalous diffraction, selenomethionine or heavy atom anomalous diffraction. SHELXC/D/E [32], SOLVE [33], RESOLVE [34], PHENIX [35] and CNS [36] and programs implemented under the CCP4 package were used to phase and refine structures [37]. COOT [38] and X-Fit [39] were used for model building.



**Fig. 2** Protein purification in the SPoRT laboratory. **a** Schematic representation of the fully automated purification. **b** Chromatogram of fully automated purification showing the Ni-NTA, desalting and gel filtration peaks

CCP4 REFMAC5 [40] was mainly used for refinement, although some structures were refined with PHENIX. The quality of all structures was checked with MOLPROBITY [41] and STAN (<http://xray.bmc.uu.se/usf/www.html>).

#### Protein information management system (PIMS)

Given the large volume of data produced by the project and shared between multiple researchers, a database system was required to store and process the information. A companion SPoRT funded project, Protein Information Management System (PIMS), was initiated at the same time as the SSPF to provide a laboratory information system for the project and other similar projects within the UK. The PIMS database was used to store and share experimental results within the project.

## Results and discussion

### Protein production

All targets have been divided into four groups on the basis of their origins. (1) Targets from *Sulfolobus solfataricus* and *Thermoproteus tenax* constitute the Archaea group (2) ORFs from the archaeal Pyrobaculum spherical virus (PSV) and *Sulfolobus islandicus* rudivirus (SIRV), along with ORFs from *Mycobacterium* and *Streptomyces* bacteriophages were classified as archaeal viruses and bacteriophages (3) several pathogenic bacteria make up the bacterial group; and (4), the eukaryote group consisted of proteins of human, frog and trypanosome origins. Statistics for all target groups at various stages of the pipeline are presented in Table 2. Work was stopped on a few targets



**Table 2** SPoRT laboratory pipeline scoreboard

Targets	Selected	Cloned	Work stopped <sup>a</sup>	Expression trials	Expressed	Soluble	Purified	Crystals	Structure
Bacteria	185	185	32	153	148	120	99	32	22
Archaea	70	70	9	61	60	29	27	11	9
Archaea viruses and bacteriophages	92	92	18	70	49	32	32	16	9
Eukaryotes <sup>b</sup>	9	7	–	7	7	9	9	2	2
Total	356	354	59	291	264	190	167	61	42

<sup>a</sup> Number of targets that were cloned but were not submitted for expression trials

<sup>b</sup> Two targets were provided as purified proteins by our collaborators

for two main reasons: structure of target or ortholog was determined in our laboratory or elsewhere, or bioinformatics analysis or publications suggested that the targets were either insoluble or membrane-associated.

The Gateway cloning system was adopted and modified by the SPoRT laboratory. This cloning strategy is independent of restriction enzymes, thus permitting standardized conditions for all of our cloning needs. We found our modified version to be very efficient for our experiments. Although PCR reactions using the double-stranded common and gene-specific primers yielded sufficient PCR product with our standardized cycles, amplification of GC rich sequences predictably yielded less PCR product. The amplified PCR fragments were successfully used for BP recombination with the protocol described. Transformation of *E. coli* cells with 2 µl of the recombination reaction produced more than 30 colonies on all plates with >99% of the isolated pDEST14 clones containing the right inserts. Intermittent sequencing of cloned genes showed that there was no significant increase in the rate of mutation during the cloning process. Overall, we found this strategy to be very robust as over 350 targets were transferred successfully to the vector, irrespective of the origin of the gene.

Our expression strategy involved the use of three different variables comprising expression strain, growth medium and temperature. At the outset of the project, three *E. coli* (DE3) expression strains (BL21, C43 and Codon Plus) were screened for expression. The rationale for including *E. coli* BL21(DE3) Codon Plus was to overcome the anticipated codon bias of archaeal and eukaryotic genes. However, preliminary results from small scale expression trials using this strain showed that expression levels were not improved, and therefore further usage was discontinued. The C43(DE3) strain is particularly useful for expression of toxic proteins in *E. coli* [42, 43]. Initial expression trials comparing C43(DE3) and BL21(DE3) cells revealed that the former was particularly beneficial for expression of the archaeal viral proteins. Overall, 67% of targets scaled-up were expressed in C43(DE3) and the rest in BL21(DE3). Growth media employed in our facility consisted of LB, TPB and auto-induction media. We found

the auto-induction media to be particularly useful for small-scale expression screening as it facilitated parallel screening by eliminating the need to measure cell densities prior to induction. However, since most of the targets were equally soluble using either TPB or LB, we opted for these relatively inexpensive and simpler media at the scale-up stage. Consequently, only 4% of proteins were scaled-up using auto-induction media, with the rest shared equally between LB and TPB. Targets scaled-up using auto-induction media and TPB were those that either expressed at the 1S level or a minority that did not express at all in LB media. Overall 72% (190/264) of all expressed targets were soluble (Table 2), a success rate attributable to the different expression systems and conditions utilized by the SPoRT laboratory. Although protein targets of prokaryotic origins constitute most of the soluble proteins (63%; 120/190), it is not certain if this is due to the larger number of prokaryotic targets compared to the others or the use of *E. coli* for expression. The majority of soluble targets expressed sufficiently: 27% at the 3S level, 60% at the 2S level, and 13% at the 1S level. It was tempting to rescue insoluble proteins using fusion proteins such as MBP and thioredoxin, but we were not convinced that this would significantly increase the overall number of soluble targets. Moreover, this would require more manpower and resources. All soluble proteins scaled-up successfully, although the volume of media had to be adjusted depending on the expression level. Typically 2 l of culture was grown for 3S proteins, 4 l for 2S proteins and 6 l for 1S proteins.

Initially, small-scale cell lysis was carried out using Bugbuster for convenience. Eventually, this was replaced by sonication for two main reasons. Firstly, we observed that higher protein yields of poorly-expressing proteins were recovered by sonication compared to Bugbuster. Secondly, we observed that in certain cases, protein yields were inconsistent between estimated and final yields from large-scale cultures, presumably due to the detergents in Bugbuster. Although not convenient for a high-throughput approach, we adopted sonication in order to eliminate any ambiguities. A consistent and practical plan was adopted for the expression process in order to feed the pipeline

continuously with proteins for processing. Typically, up to twenty targets were chosen per week for expression trials. Concurrently, proteins judged to be soluble from the previous week and confirmed by mass spectrometry were prepared in large quantities. The BioSprint 15 workstation, which can perform 15 nickel pull-down experiments in about 30 min, expedited sample processing times. Additionally, the Nanodrop Spectrophotometer was very beneficial as it provided a quick, easy and efficient means for not only measuring optical densities of cultures, but also spectra of DNA and proteins. As it was never the case that all twenty proteins were soluble, up to ten proteins were scaled up per week and passed on for purification. All protein expression experiments were routinely carried out on a weekly basis by one technician, with one PDRA trouble-shooting problems such as conflicting expression and mass spectrometry results. Such problems were usually resolved by repeating the trials and/or gene sequencing.

Affinity tags are ideal for HTP protein purification because a single chromatography method can be adopted. The advantages of using the His<sub>6</sub>-tag are well-documented. Using either manual or fully-automated purification methods, we obtained >90% protein purity in sufficient amounts for about 88% (167/190) of all soluble proteins. A typical elution profile for proteins purified using the fully-automated version is shown in Fig. 2b, with clearly identifiable Ni<sup>2+</sup>-IMAC, DS and GF peaks. The fully-automated method, incorporating on-line off-column TEV cleavage, was made possible by the inclusion of the 50-ml superloop in-series, as described in Materials and Methods. This method required no user-intervention once the sample was applied to the system. Also, the fully-automated method was less time-consuming, eliminating all manual handling steps such as sample loading and pooling between each chromatographic step. TEV cleavage using the fully-automated method was just as efficient as the manual method. Up to ten proteins were routinely purified per week by one technician. However, in several cases, it was difficult to control the final volume of eluates from all columns leading up to the GF column, which is limited to a maximum permissible volume of 5 ml. Elution volumes from chromatography steps prior to GF were typically larger than this volume. The outcome of this was that only 50% of the purified protein eventually made it to GF. In the latter stages of the project, after several unsuccessful attempts were made to rectify the situation, we simply purified all our targets manually. Consequently, the number of proteins purified weekly reduced to about six.

### Crystallization and crystal structures

All purified protein samples were screened successfully using the nanolitre-scale Rhombix-Hamilton-Thermo

integrated system. This technology not only reduced protein production costs (final protein yield was not always important), but allowed for immediate setting up of crystal trials soon after purification. As shown in Table 2, 61 of the 167 purified proteins (37%) formed diffraction-quality crystals. Despite the nanolitre-scale size of the crystallization drops, most of the crystals obtained were robust enough to provide complete datasets suitable for structural determination. As shown in Table 2, 42 structures have been solved thus far, representing 25% (42/167) of the targets that entered crystallization trials. Different phasing methods were used for structure determination with two-thirds of the structures using methods other than molecular replacement (see Table 3). This outcome was anticipated since most of the SPoRT target sequences did not display significant homology (>20%) with protein sequences in all databases at the outset of the project.

### Retrospective analysis of target selection

Protein crystallization propensity predictors such as OB-Score, ParCrys, Xtalpred [44] are widely utilized by structural genomics groups for target selection. At the initial stages of this project, some proteins were prioritized using the pI/GRAVY crystallization predictor, which groups proteins into clusters A to C, with A being the most likely to crystallize and C the least likely. Significantly, proteins in Cluster C are predominantly membrane proteins. Preference was given to proteins that fell into either cluster A or B. In order to gain further insight into the efficacy of these predictors, we have carried out a retrospective analysis of all structures determined in our laboratory. XtalPred uses a scale of one to five, with one being the most likely to crystallize and five being the least. ParCrys predicts sequences to be high-scoring, amenable or recalcitrant. As shown in Table 3, 44% (18 out of 42) of the structures would not have been selected if Xtalpred was used initially to select targets. In the case of ParCrys and pI/GRAVY, this would have been 34% (14 out of 42) and 39% (16 out of 42) respectively. It is noteworthy to mention here that the pI/GRAVY analysis revealed that the targets were grouped into either Clusters A or B but never Cluster C. Consequently, 61% of the targets were exclusively outliers (as denoted in Table 3), and therefore would not have been selected. Although these results suggest that the predictors are not perfect, we observe that the 'un-crystallizable proteins' are dominated by the PSV and SIRV ORFs with sequences unlike any other functionally characterized protein. Pairwise comparisons reveal that conflicting outcomes (i.e. one predictor suggests that the protein is crystallizable whereas another suggests otherwise) are predicted for 14 proteins by XtalPred versus ParCrys, 13 proteins by XtalPred versus pI/GRAVY plot

**Table 3** Summary of all SPoRT laboratory crystal structures showing phasing methods, origins and functions of proteins, and retrospective analysis of all structurally characterized targets using three crystallization predictors

Structures	Phasing method	Origin	Function/comments	Retrospective analysis of target selection			PDB code [reference]
				XtalPred	ParCrys	Cluster	
<i>Bacteria</i>							
pqsE	MR	<i>Pseudomonas aeruginosa</i>	Quinolone signal response protein	4	High-scoring	A	2VW8
pqsL	Sm	<i>P. aeruginosa</i>	Probable FAD-dependent monooxygenase	1	High-scoring	A	2X3N
PA4511	MR	<i>P. aeruginosa</i>	Uncharacterized	1	High-scoring	A	2X5E
PA4631	Lead	<i>P. aeruginosa</i>	Nucleoside-diphosphate-sugar epimerase	4	Recalcitrant	–	2X4G
PA4715	MR	<i>P. aeruginosa</i>	Probable aminotransferase	3	Amenable	B	2X5D
PA0856	Se-SAD	<i>P. aeruginosa</i>	Uncharacterized	4	Recalcitrant	–	2X3O
FabH	MR	<i>P. aeruginosa</i>	3-Oxoacyl-[acyl-carrier-protein] synthase III	2	Recalcitrant	A	2X3E
AcsD	Se-SAD	<i>Pectobacterium chrysanthemi</i>	Achromobactin synthetase	4	High-scoring	A	3FFE [45]
AlcC	SIRAS	<i>Bordetella bronchiseptica</i>	Alcaligin biosynthesis protein C	3	High-scoring	A	2X0O
DesE	Br	<i>Streptomyces coelicolor</i>	Putative ferric-siderophore receptor protein	4	High-scoring	A	2X4L
Fbabb	Pt	<i>Streptococcus pyogenes</i>	Fibronectin binding protein	3	Recalcitrant	A	2X5P
MRSA677 (Sar2028)	MR	Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)	Asp/Tyr/Phe pyridoxal-5'-phosphate-dependent aminotransferase	4	High-scoring	A	2X5F
MRSA681 (Sar2676)	MR	MRSA	Pantothenate synthetase	1	High-scoring	A	2X3F
MVAK (QGJ78)	Sm & Pt	MRSA	Mevalonate kinase	1	Amenable	A	2X7I
SAR0482	Se-SAD	MRSA	Orn/Lys/Arg decarboxylase family protein	2	High-scoring	A	2X3L
SAR1376	Zn	MRSA	Putative 4-oxalocrotonate tautomerase	5	Amenable	–	2X4K
PPFK (Q6GIU3)	MR	MRSA	Putative phosphofructokinase	1	Amenable	A	2JG5
TAG (Q6GG41)	Zn-SAD	MRSA	DNA-3-methyladenine glycosylase I	1	High-scoring	A	2JG6
SPT	MR	<i>Sphingomonas paucimobilis</i>	Serine palmitoyl transferase	2	Amenable	A	2JG2 [56]
ArdA	Pt	Transposon Tn916	Antirestriction protein	3	Recalcitrant	–	2W82 [57]
ArdB	Pt	<i>Escherichia coli</i>	Antirestriction protein	4	Recalcitrant	A	2WJ9
VC1805	MIRAS	<i>Vibrio cholerae</i>	Hypothetical protein	4	High-scoring	A	2V1L [58]
<i>Archaea</i>							
SSo1986	K and Pb	<i>S. solfataricus</i>	Uncharacterized	1	Amenable	–	2X5Q
SSo2273	Fe-SAD	<i>S. solfataricus</i>	Uncharacterized	3	Amenable	–	2X4H
SSo2452	MR	<i>S. solfataricus</i>	ATPase	4	Amenable	–	2W0M [50]
SSo6206	Se-SAD	<i>S. solfataricus</i>	Uncharacterized	3	Recalcitrant	A	2X3D
PCNA	MR	<i>S. solfataricus</i>	DNA processivity factor	3	Amenable	A	2IX2 [51]
XPD	Se-SAD	<i>S. solfataricus</i>	DNA repair helicase	3	Amenable	–	2VL7 [48]
SSo2462	MR	<i>S. solfataricus</i>	DNA repair helicase	4	Amenable	–	2VA8 [49]
SSo1404	MR	<i>S. solfataricus</i>	Uncharacterized	3	Amenable	–	2IVY

**Table 3** continued

Structures	Phasing method	Origin	Function/comments	Retrospective analysis of target selection			PDB code [reference]
				XtalPred	ParCrys	Cluster	
Ard1		<i>S. solfataricus</i>	N-terminal acetylase	3	Recalcitrant	–	2X7B
<i>Archaea viruses and bacteriophages</i>							
SIRV-ORF114 (CAG38848)	MR	<i>Sulfolobus islandicus</i> rudivirus (SIRV)	Uncharacterized	2	High-scoring	A	2X4I
SIRV-ORF131 (CAG38830)	Se-SAD	SIRV	Uncharacterized	4	Recalcitrant	–	Sm-2X5G; Dm-2X5H
SIRV-ORF55 (CAG38821)	Zn-SAD	SIRV	Uncharacterized	5	Recalcitrant	–	2X48
SIRV-ORF119 (CAG38829)	Se-SAD	SIRV	Uncharacterized	5	Recalcitrant	–	2X3G
PSV-ORF131	S-SAD	<i>Pyrobaculum</i> spherical virus (PSV)	Uncharacterized	4	Recalcitrant	–	2X5C
PSV-ORF137	Se-SAD	PSV	Uncharacterized	3	Recalcitrant	–	2X4J
PSV-ORF165a	Se-SAD	PSV	Uncharacterized	4	Recalcitrant	–	2VXZ
PSV-ORF239	Sulphur-SAD	PSV	Uncharacterized	5	High-scoring	A	2X3M
PSV-ORF126	Zn-SAD	PSV	Uncharacterized	3	Recalcitrant	B	2X5R
<i>Eukaryotes</i>							
Ranasmurfin	Zn-SAD	<i>Polypedates leucomystax</i>	Uncharacterized	4	Amenable	A	2VH3 [54]
Cathepsin-L mutant	MR	Human	Silica polymerization	3	Amenable	A	2VHS [59]

The PDB code for each structure is indicated

and 11 proteins by ParCrys versus pI/GRAVY plot. This discrepancy may be due to different parameters utilized by the predictors namely; size, homologs in PDB, GRAVY index and pI. Therefore, it is reasonable to suggest that at least two predictors should be utilized in order to provide a wider coverage of crystallization space.

### Scientific highlights

Reports describing the crystal structures and biochemical analyses of 10 SPoRT-generated targets have been published in peer-reviewed journals (see Table 3 for references). Experimental details of crystal structures yet to be published are presented in Supplementary information. Below, we summarize a few examples to highlight the scientific impact of a few of our accomplishments.

Iron is an essential nutrient and microorganisms synthesize low molecular weight high affinity iron chelators (siderophores) in order to sequester environmental or host iron. The synthesis of these compounds is both a potential antibacterial target and of interest biochemically. We have reported the crystal structure and biochemical analysis of AcsD, an enzyme involved in the biosynthesis of

achromobactin from the Gram negative plant pathogen *Pectobacterium chrysanthemi* [45] and the structure of AlcC, a new member of the superfamily, will be reported in due course. Other antimicrobial targets included those selected from *Pseudomonas aeruginosa*, an opportunistic antibiotic-resistant human pathogen. The *Pseudomonas* quinolone signal (PQS) is implicated in both pathogenesis and formation of biofilms and was of particular interest. In total eight *P. aeruginosa* structures have been determined. Methicillin-resistant *Staphylococcus aureus* (MRSA) is the cause of considerable concern in hospitals. We employed comparative two-dimensional gel analysis and mass spectrometry [46, 47] to identify proteins that were either upregulated or downregulated in MRSA compared to methicillin-sensitive *S. aureus* (MSSA), and therefore considered to be essential with potentially novel folds. Seven structures have been determined from this target.

Archaeal proteins are frequently used as tools to understand equivalent proteins in eukaryotes, most particularly those involved in DNA replication and repair. Of the 61 archaeal targets selected, 60 expressed, about half were soluble and nine structures were determined. These included crystal structures of two helicases implicated in DNA

repair: XPD from *S. tokodaii* [48] and hel308 from *S. solfataricus* [49], a RadA paralog [50] and a heterotrimeric PCNA sliding clamp [51].

*Sulfolobus islandicus* rudivirus (SIRV) and *Pyrobaculum* spherical virus (PSV) are dsDNA viruses that infect archaea and their proteins show little or no detectable homology to any proteins of known function [52, 53]. We reasoned that structural data from these viruses could help elucidate viral protein function and improve our understanding of viral evolution. The virus genomes (48 ORFs from SIRV and 45 ORFs from PSV) were of a suitable size for us to attempt complete coverage. We were able to determine eight structures having cloned and attempted to express all genes.

Biological research is of course very broad but we were able to contribute to a number of local projects by providing structural data. The most striking was a novel protein harvested from the foam nests of *Polypedates leucomystax*, a tropical frog species from Malaysia. The crystal structure of the protein, named ranasmurfín, revealed intra- and inter-molecular cross-links featuring the lysine-tyrosine quinone (LTQ) co-factor. At 1.16 Å resolution, the amino acid sequence was identified directly from the electron density map and verified by mass spectrometry to be a novel protein [54].

## Conclusions

It is clear from many studies that structure determination can be largely automated and the efficiency greatly improved. What is more, our effort demonstrates that this can be carried out on a relatively small scale and be focused to deliver results to the scientific community. The ability to run such a pipeline appears to be a skill in itself. Our own efficiency improved year on year as new working practices and approaches developed with experience. Despite this success, we have not been able to reach the point of guaranteeing a structure for every target nor in being able a priori to identify which targets will give structures. Target selection is improving and new tools are emerging that should continue to drive up the target to structure ratio (reviewed in [55]), although this is not the same as a structure for every biological target. A small group can gain efficiency by being able to adjust and alter procedures. For example, we found the use of heavy atoms a very efficient first attempt to solve structures rather than always proceeding to selenomethionine.

Our experience is that a structural biology laboratory within a collaborative centre, bringing the techniques of modern structural biology to bear on novel problems, has some advantages. The pipeline has the capacity to move very quickly to respond to a scientific need. Personnel who

run the pipeline improved in efficiency over the time of the project. In a collaboration, the expertise of those carrying out the structural biology can be leveraged in the analysis of the structure, design and interpretation of subsequent experiments.

Efficiency and automation require significant intellectual resources. We observe that in this lies an issue for the future. Even in our relatively small scale effort, we were unable to match the productivity of the pipeline at generating structures with publication. Only in cases where targets were carefully chosen in advance or the structure was immediately scientifically significant, were we able to follow this more traditional path to publications. With collaborations, we were able to perform significant biochemical analysis for some proteins. However, as we report, many structures have been determined with very limited or no analysis. By fully reporting the experimental detail and depositing the data, we aim to prompt others to perform this analysis.

**Acknowledgments** THE SSPF was supported by grants from The Scottish Funding Council (references SSPF and SULSA), The Biotechnology and Biological Sciences Research Council (reference BB/S/B14450), European Union under framework 7 (reference Aeropath)

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited..

## References

1. Banci L, Bertini I, Cusack S, de Jong RN, Heinemann U, Jones EY, Kozielski F, Maskos K, Messerschmidt A, Owens R, Perakis A, Poterszman A, Schneider G, Siebold C, Silman I, Sixma T, Stewart-Jones G, Sussman JL, Thierry JC, Moras D (2006) First steps towards effective methods in exploiting high-throughput technologies for the determination of human protein structures of high biomedical value. *Acta Crystallogr D Biol Crystallogr* 62(Pt 10):1208–1217
2. Lee WH, Atienza-Herrero J, Abagyan R, Marsden BD (2009) SGC—structural biology and human health: a new approach to publishing structural biology results. *PLoS One* 4(10):e7675
3. Bendtsen JD, Nielsen H, von Heijne G, Brunak S (2004) Improved prediction of signal peptides: SignalP 3.0. *J Mol Biol* 340(4):783–795
4. Krogh A, Larsson B, von Heijne G, Sonnhammer EL (2001) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. *J Mol Biol* 305(3): 567–580
5. Li X, Romero P, Rani M, Dunker AK, Obradovic Z (1999) Predicting protein disorder for N-, C-, and internal regions. *Genome Inform Ser Workshop Genome Inform* 10:30–40
6. Yang ZR, Thomson R, McNeil P, Esnouf RM (2005) RONN: the bio-basis function neural network technique applied to the

- detection of natively disordered regions in proteins. *Bioinformatics* 21(16):3369–3376
7. Canaves JM, Page R, Wilson IA, Stevens RC (2004) Protein biophysical properties that correlate with crystallization success in *Thermotoga maritima*: maximum clustering strategy for structural genomics. *J Mol Biol* 344(4):977–991
  8. Overton IM, van Niekerk CA, Carter LG, Dawson A, Martin DM, Cameron S, McMahon SA, White MF, Hunter WN, Naismith JH, Barton GJ (2008) TarO: a target optimisation system for structural biology. *Nucleic Acids Res* 36(Web Server issue):W190–W196
  9. Overton IM, Barton GJ (2006) A normalised scale for structural genomics target ranking: the OB-score. *FEBS Lett* 580(16):4005–4009
  10. Overton IM, Padovani G, Girolami MA, Barton GJ (2008) ParCrys: a Parzen window density estimation approach to protein crystallization propensity prediction. *Bioinformatics* 24(7):901–907
  11. Peterson JD, Umayam LA, Dickinson T, Hickey EK, White O (2001) The comprehensive microbial resource. *Nucleic Acids Res* 29(1):123–125
  12. Hubbard TJ, Aken BL, Beal K, Ballester B, Caccamo M, Chen Y, Clarke L, Coates G, Cunningham F, Cutts T, Down T, Dyer SC, Fitzgerald S, Fernandez-Banet J, Graf S, Haider S, Hammond M, Herrero J, Holland R, Howe K, Johnson N, Kahari A, Keefe D, Kokocinski F, Kulesha E, Lawson D, Longden I, Melsopp C, Megy K, Meidl P, Ouverdin B, Parker A, Prlic A, Rice S, Rios D, Schuster M, Sealy I, Severin J, Slater G, Smedley D, Spudich G, Trevanion S, Vilella A, Vogel J, White S, Wood M, Cox T, Curwen V, Durbin R, Fernandez-Suarez XM, Flicek P, Kasprzyk A, Proctor G, Searle S, Smith J, Ureta-Vidal A, Birney E (2007) Ensembl 2007. *Nucleic Acids Res* 35(Database issue):D610–D617
  13. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 25(17):3389–3402
  14. Rost B (1999) Twilight zone of protein sequence alignments. *Protein Eng* 12(2):85–94
  15. Berman H, Henrick K, Nakamura H, Markley JL (2007) The worldwide protein data bank (wwPDB): ensuring a single, uniform archive of PDB data. *Nucleic Acids Res* 35(Database issue):D301–D303
  16. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ, Natale DA, O'Donovan C, Redaschi N, Yeh LS (2004) UniProt: the universal protein knowledgebase. *Nucleic Acids Res* 32(Database issue):D115–D119
  17. Bateman A, Coin L, Durbin R, Finn RD, Hollich V, Griffiths-Jones S, Khanna A, Marshall M, Moxon S, Sonnhammer EL, Studholme DJ, Yeats C, Eddy SR (2004) The Pfam protein families database. *Nucleic Acids Res* 32(Database issue):D138–D141
  18. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, Richter J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H, Eppig JT, Hill DP, Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie KR, Costanzo MC, Dwight SS, Engel S, Fisk DG, Hirschman JE, Hong EL, Nash RS, Sethuraman A, Theesfeld CL, Botstein D, Dolinski K, Feierbach B, Berardini T, Mundodi S, Rhee SY, Apweiler R, Barrell D, Camon E, Dimmer E, Lee V, Chisholm R, Gaudet P, Kibbe W, Kishore R, Schwarz EM, Sternberg P, Gwinn M, Hannick L, Wortman J, Berriman M, Wood V, de la Cruz N, Tonellato P, Jaiswal P, Seigfried T, White R (2004) The gene ontology (GO) database and informatics resource. *Nucleic Acids Res* 32(Database issue):D258–D261
  19. Wootton JC, Federhen S (1996) Analysis of compositionally biased regions in sequence databases. *Methods Enzymol* 266:554–571
  20. Forsyth RA, Haselbeck RJ, Ohlsen KL, Yamamoto RT, Xu H, Trawick JD, Wall D, Wang L, Brown-Driver V, Froelich JM, Kedar GC, King K, McCarthy M, Malone C, Misiner B, Robbins D, Tan Z, Zhu ZY, Carr G, Mosca DA, Zamudio C, Foulkes JG, Zyskind JW (2002) A genome-wide strategy for the identification of essential genes in *Staphylococcus aureus*. *Mol Microbiol* 43(6):1387–1400
  21. Ji Y, Zhang B, Van SF, Horn WP, Woodnutt G, Burnham MK, Rosenberg M (2001) Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. *Science* 293(5538):2266–2269
  22. Liu H, Naismith JH (2009) A simple and efficient expression and purification system using two newly constructed vectors. *Protein Expr Purif* 63(2):102–111
  23. Studier FW (2005) Protein production by auto-induction in high density shaking cultures. *Protein Expr Purif* 41(1):207–234
  24. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227(5259):680–685
  25. Guerrero SA, Hecht HJ, Hofmann B, Biebl H, Singh M (2001) Production of selenomethionine-labelled proteins using simplified culture conditions and generally applicable host/vector systems. *Appl Microbiol Biotechnol* 56(5–6):718–723
  26. Kapust RB, Tozser J, Fox JD, Anderson DE, Cherry S, Copeland TD, Waugh DS (2001) Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. *Protein Eng* 14(12):993–1000
  27. Rupp B (2003) Maximum-likelihood crystallization. *J Struct Biol* 142(1):162–169
  28. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. In: *Methods in enzymology*. Academic Press, New York, pp 307–326
  29. Leslie AGW (1992) Recent changes to the MOSFLM package for processing film and image plate data. *Joint CCP4 + ESF-EA-MCB newsletter on protein crystallography*, no. 26
  30. Evans P (2006) Scaling and assessment of data quality. *Acta Crystallogr D Biol Crystallogr* 62(Pt 1):72–82
  31. Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. *J Appl Crystallogr* 26:795–800
  32. Schneider TR, Sheldrick GM (2002) Substructure solution with SHELXD. *Acta Crystallogr D Biol Crystallogr* 58(Pt 10 Pt 2):1772–1779
  33. Terwilliger TC, Berendzen J (1999) Automated MAD and MIR structure solution. *Acta Crystallogr D Biol Crystallogr* 55(Pt 4):849–861
  34. Terwilliger TC (2000) Maximum-likelihood density modification. *Acta Crystallogr D Biol Crystallogr* 56(Pt 8):965–972
  35. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC (2002) PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallogr D Biol Crystallogr* 58(Pt 11):1948–1954
  36. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL (1998) Crystallography & NMR system: a new software suite for macromolecular structure determination. *Acta Crystallogr D Biol Crystallogr* 54(Pt 5): 905–921
  37. Collaborative Computational Project N (1994) The CCP4 suite: programs for protein crystallography. *Acta Crystallogr D Biol Crystallogr* 50(Pt 5):760–763

38. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 60(Pt 12 Pt 1):2126–2132
39. McRee DE (1999) XtalView/Xfit—a versatile program for manipulating atomic coordinates and electron density. *J Struct Biol* 125(2–3):156–165
40. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr D Biol Crystallogr* 53(Pt 3):240–255
41. Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB, 3rd, Snoeyink J, Richardson JS, Richardson DC (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res* 35(Web Server issue):W375–W383
42. Dumon-Seignovert L, Cariot G, Vuillard L (2004) The toxicity of recombinant proteins in *Escherichia coli*: a comparison of over-expression in BL21(DE3), C41(DE3), and C43(DE3). *Protein Expr Purif* 37(1):203–206
43. Miroux B, Walker JE (1996) Over-production of proteins in *Escherichia coli*: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. *J Mol Biol* 260(3):289–298
44. Slabinski L, Jaroszewski L, Rychlewski L, Wilson IA, Lesley SA, Godzik A (2007) XtalPred: a web server for prediction of protein crystallizability. *Bioinformatics* 23(24):3403–3405
45. Schmelz S, Kadi N, McMahon SA, Song L, Oves-Costales D, Oke M, Liu H, Johnson KA, Carter LG, Botting CH, White MF, Challis GL, Naismith JH (2009) AcsD catalyzes enantioselective citrate desymmetrization in siderophore biosynthesis. *Nat Chem Biol* 5(3):174–182
46. Seetharamappa J, Oke M, Liu H, McMahon SA, Johnson KA, Carter L, Dorward M, Zawadzki M, Overton IM, van Niekirk CA, Graham S, Botting CH, Taylor GL, White MF, Barton GJ, Coote PJ, Naismith JH (2007) Expression, purification, crystallization, data collection and preliminary biochemical characterization of methicillin-resistant *Staphylococcus aureus* Sar2028, an aspartate/tyrosine/phenylalanine pyridoxal-5'-phosphate-dependent aminotransferase. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 63(Pt 5):452–456
47. Seetharamappa J, Oke M, Liu H, McMahon SA, Johnson KA, Carter L, Dorward M, Zawadzki M, Overton IM, van Niekirk CA, Graham S, Botting CH, Taylor GL, White MF, Barton GJ, Coote PJ, Naismith JH (2007) Purification, crystallization and data collection of methicillin-resistant *Staphylococcus aureus* Sar2676, a pantothenate synthetase. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 63(Pt 6):488–491
48. Liu H, Rudolf J, Johnson KA, McMahon SA, Oke M, Carter L, McRobbie AM, Brown SE, Naismith JH, White MF (2008) Structure of the DNA repair helicase XPD. *Cell* 133(5):801–812
49. Richards JD, Johnson KA, Liu H, McRobbie AM, McMahon SA, Oke M, Carter L, Naismith JH, White MF (2008) Structure of the DNA repair helicase hel308 reveals DNA binding and autoinhibitory domains. *J Biol Chem* 283(8):5118–5126
50. McRobbie AM, Carter LG, Kerou M, Liu H, McMahon SA, Johnson KA, Oke M, Naismith JH, White MF (2009) Structural and functional characterisation of a conserved archaeal RadA paralog with antirecombinase activity. *J Mol Biol* 389(4):661–673
51. Williams GJ, Johnson K, Rudolf J, McMahon SA, Carter L, Oke M, Liu H, Taylor GL, White MF, Naismith JH (2006) Structure of the heterotrimeric PCNA from *Sulfolobus solfataricus*. *Acta Crystallogr Sect F Struct Biol Cryst Commun* 62(Pt 10):944–948
52. Haring M, Peng X, Brugger K, Rachel R, Stetter KO, Garrett RA, Prangishvili D (2004) Morphology and genome organization of the virus PSV of the hyperthermophilic archaeal genera *Pyrobaculum* and *Thermoproteus*: a novel virus family, the Globuloviridae. *Virology* 323(2):233–242
53. Peng X, Blum H, She Q, Mallok S, Brugger K, Garrett RA, Zillig W, Prangishvili D (2001) Sequences and replication of genomes of the archaeal rudiviruses SIRV1 and SIRV2: relationships to the archaeal lipothrixvirus SIFV and some eukaryal viruses. *Virology* 291(2):226–234
54. Oke M, Ching RT, Carter LG, Johnson KA, Liu H, McMahon SA, White MF, Bloch C Jr, Botting CH, Walsh MA, Latiff AA, Kennedy MW, Cooper A, Naismith JH (2008) Unusual chromophore and cross-links in ranasmurfín: a blue protein from the foam nests of a tropical frog. *Angew Chem Int Ed Engl* 47(41):7853–7856
55. Marsden RL, Orengo CA (2008) Target selection for structural genomics: an overview. *Methods Mol Biol* 426:3–25
56. Yard BA, Carter LG, Johnson KA, Overton IM, Dorward M, Liu H, McMahon SA, Oke M, Puech D, Barton GJ, Naismith JH, Campopiano DJ (2007) The structure of serine palmitoyltransferase; gateway to sphingolipid biosynthesis. *J Mol Biol* 370(5):870–886
57. McMahon SA, Roberts GA, Johnson KA, Cooper LP, Liu H, White JH, Carter LG, Sanghvi B, Oke M, Walkinshaw MD, Blakely GW, Naismith JH, Dryden DT (2009) Extensive DNA mimicry by the ArdA anti-restriction protein and its role in the spread of antibiotic resistance. *Nucleic Acids Res* 37(15):4887–4897
58. Sheikh MA, Potter JA, Johnson KA, Sim RB, Boyd EF, Taylor GL (2008) Crystal structure of VC1805, a conserved hypothetical protein from a *Vibrio cholerae* pathogenicity island, reveals homology to human p32. *Proteins* 71(3):1563–1571
59. Fairhead M, Johnson KA, Kowatz T, McMahon SA, Carter LG, Oke M, Liu H, Naismith JH, van der Walle CF (2008) Crystal structure and silica condensing activities of silicatein alpha-cathepsin L chimeras. *Chem Commun (Camb)* 15:1765–1767